Case 2: Treatment-Experienced nAMD Switch to Aflibercept 8mg
David Eichenbaum, MD, FASRS concludes this series with the final case of a treatment-experienced patient switching from aflibercept 2 mg to high-dose aflibercept 8 mg with noticeable improvement after the first dose.
Summary
David Eichenbaum, MD, FASRS presents the second case, wrapping up with key insights from the cases in this series. The second case involved an 88-year-old patient with neovascular macular degeneration, initially treated with aflibercept 2 mg every 5 to 6 weeks. The patient had good outcomes, but Eichenbaum sought to improve both anatomy and visit frequency. The patient was switched from aflibercept 2 mg to aflibercept 8 mg. After the first injection, there was a notable improvement in anatomy and visual acuity. Subsequently, the patient was extended to an 8-week interval, showcasing positive outcomes.
Regarding the choice between aflibercept 8 milligrams and faricimab, Eichenbaum finds it challenging, expressing that both are excellent drugs. He hopes for clearer guidance on which patients may benefit more from one over the other. In his practice, that decision often relies on individual patient response to treatment.
This summary was AI-generated and edited for clarity.
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
